Description
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
Location: San Francisco (CPMC)
Please contact: clinicalresearch@sutterhealth.org about study CheckMate73L
View study details on ClinicalTrials.govPrincipal Investigator
Co-Investigator(s)
Ari Baron, M.D., Caroline Behler, MD, Alan Kramer, MD, Wei Wang, MD
Recruitment Status
Active, Recruiting
Related Studies
SEER Lung Cancer
SEER-Lung: A Prospective Blood Sample Collection Study to Develop and Validate a Panel
of Proteinbased Biomarkers in Patients with Pulmonary Nodules
Investigator: Tze-Ming Chen, M.D., FCCP
The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity
Using EHR from a large healthcare system in Northern CA, we will study the impact
of smoking, comorbidities, race on COVID-19 infection and disease severity.
Investigator: Jiang Li, Ph.D., MPH